A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-224
- Sponsors Merck Sharp & Dohme
- 15 May 2017 Planned End Date changed from 24 Aug 2017 to 25 Feb 2019.
- 08 Feb 2017 Planned End Date changed from 1 Nov 2017 to 1 Aug 2017.
- 08 Feb 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2017.